Pfizer Says Xalkori Gets Conditional OK to Treat in EU
Pfizer Inc. announced today that the European Commission has given conditional marketing authorization for XALKORI^® (crizotinib) in the European Union (EU) for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
“In the field of metastatic non-small cell lung cancer, XALKORI represents a major advancement. It brings to the patients with ALK-translocated tumors an oral compound that can achieve tumor shrinkage and delay disease progression,” said Dr. Jean-Charles Soria, professor of Medicine and Medical Oncology at South-Paris University and cancer specialist at Institut Gustave Roussy, France.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.